SAGITTARIUS at the 3rd Horizon Europe Cancer Mission “Diagnosis and Treatment – Refractory Cancers” Cluster Meeting

Madrid, 22 October 2026 

 

On 22 October 2026, the SAGITTARIUS consortium took part in the 3rd Horizon Europe Cancer Mission “Diagnosis and treatment – Refractory Cancers” Cluster meeting, hosted by Asociación Española Contra el Cáncer in Madrid, Spain. The annual gathering brought together representatives from the 13 projects funded under the Cancer Mission cluster to share progress, discuss common challenges, and strengthen collaboration across initiatives.

The Meeting

During the project presentation session, each Cancer Mission project provided a concise overview of its objectives, current activities, and key achievements to date, offering participants a valuable opportunity to gain insight into the progress being made across the cluster and to identify potential areas for future collaboration. Ylenia Silvestri (IFOM) presented the latest developments from the SAGITTARIUS project, highlighting its objectives, study design, and progress.

SAGITTARIUS also actively contributed to the discussions dedicated to the Cluster’s Working Groups, including data management, dissemination and communication, research and innovation, citizen engagement, and the reduction of inequalities in cancer care.

The discussion on WG1 – Collaborative Framework and Data Management was moderated by Sarah Machiavelli (SporeData), a member of the SAGITTARIUS consortium. The session built on the results of surveys circulated among cluster projects in advance of the meeting and explored opportunities to improve data sharing, collaboration frameworks, and common approaches to data management.

During the WG2 – Dissemination and Communication of the Results round table, participants took part in an interactive workshop designed to translate into practical actions the work carried out during two virtual workshops held earlier this year. These activities were aimed at better understanding patients’ needs and experiences. Working in small groups, participants discussed potential barriers faced by patients when joining or participating in clinical trials and proposed ideas and solutions to address them. The outcomes of this exercise will be further developed in the coming months and presented during a future virtual cluster session.

The WG3 – Research and Innovation discussion provided an opportunity to exchange experiences and identify common challenges and opportunities for collaborative research across the projects.

In the WG4 – Citizen Engagement session, participants discussed a series of key questions that will form the basis of a forthcoming cluster-wide survey, with the aim of strengthening patient and citizen involvement in Cancer Mission activities.

Finally, the WG5 – Addressing Inequalities discussion reviewed the results of two dedicated surveys and provided an update on the development of a Cluster white paper focused on reducing inequalities in cancer prevention, diagnosis, treatment, and access to innovation across Europe.

Next steps

 Looking ahead, the next cluster-wide outputs will include the Annual Meeting Conclusions document, summarising the key messages and recommendations emerging from the meeting, as well as a dedicated Research & Innovation Policy Brief aimed at supporting the long-term impact of the Cancer Mission projects and informing future European initiatives.

SAGITTARIUS is proud to contribute to this collaborative effort and to work alongside fellow projects towards improving cancer diagnosis and treatment for patients.

For more information

You can find more information about the “Diagnosis and Treatment – Refractory Cancers” Cluster at the dedicated website: https://refractorycancercluster.eu/.

For more information about the SAGITTARIUS project or to take part in the trial, please contact: clinical.trials@ifom.eu.

To be updated about the SAGITTARIUS project:

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.